Aprepitant in the Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy (Cyclophosphamide Plus Anthracyclines) in Breast Cancer Patients: a Double-blind Randomized Study
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 580
- 试验地点
- 1
- 主要终点
- Percentage of complete responses (no vomiting and no rescue treatment) on days 2-5 after chemotherapy administration
研究概览
简要总结
The aim of the study is to compare efficacy and tolerability of aprepitant versus dexamethasone in the prevention of delayed emesis induced by moderately emetogenic chemotherapy (cyclophosphamide plus anthracyclines) in breast cancer patients.
详细描述
This is a phase III, double-blind, randomized trial, to evaluated the efficacy and safety of aprepitant for the prevention of delayed emesis in patients with breast cancer submitted for the first time to chemotherapy with cyclophosphamide plus anthracyclines.
The study will be carried out during the first cycle of chemotherapy.
For the prevention of acute emesis, all patients will receive, before chemotherapy:
- dexamethasone 8 mg iv in 15 minutes, 30 minutes before chemotherapy;
- palonosetron 0.25 mg iv bolus, 30 minutes before chemotherapy
- aprepitant 125 mg orally, 60 minutes before chemotherapy
After 24 hours from chemotherapy administration, patients will be randomized to receive:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •patients with breast cancer, receiving for the first time chemotherapy with cyclophosphamide + anthracyclines (FAC, FEC, AC, EC).
- •patients over 18 years old and those who signed informed consent
- •adequate contraception if premenopausal women
- •Every other anticancer drug in the first 24 hours will be administered after the end of cyclophosphamide plus anthracycline.
排除标准
- •patients already submitted to chemotherapy
- •patients receiving any chemotherapy on days 2-4 after treatment
- •patients with concomitant severe diseases or with predisposition to emesis such as intestinal obstruction, active peptic ulcer, hypercalcemia and brain metastases
- •contraindications to corticosteroids (i.e., active peptic ulcer or previous bleeding from peptic ulcer
- •patients submitted to concomitant radiotherapy or submitted to radiotherapy in the 15 days before chemotherapy or planned to receive radiotherapy during the 8 days after chemotherapy
- •patients receiving other concomitant antiemetic treatments or submitted to antiemetic treatments in the 24 hours before chemotherapy
- •patients with nausea or vomiting in the 24 hours before chemotherapy
- •patients receiving concomitant steroids, except when administered at physiologic doses
- •patients receiving concomitant benzodiazepines, except when used for nocturnal sedation
- •patients with WBC count <3000/mm3 or platelet count <70000/mm3
- •patients who are pregnant or breast-feeding
研究组 & 干预措施
1
Aprepitant
干预措施: Aprepitant (Drug)
2
dexamethasone
干预措施: dexamethasone (Drug)
结局指标
主要结局
Percentage of complete responses (no vomiting and no rescue treatment) on days 2-5 after chemotherapy administration
时间窗: 6 days
次要结局
- Evaluation of the impact on quality of life of the two antiemetic regimens(6 days)
- Evaluation of the prognostic factors of delayed emesis in patients receiving a combination of aprepitant, palonosetron and dexamethasone for the prevention of acute emesis(6 days)
研究者
Roila Fausto
Dr
S. Maria Hospital, Terni